Literature DB >> 17452053

Identification of the neuropeptide content of individual rat neurohypophysial terminals.

Edward E Custer1, Sonia Ortiz-Miranda, Thomas K Knott, Randi Rawson, Christian Elvey, Ryan H Lee, José R Lemos.   

Abstract

The objective of this study was to develop a method that could reliably determine the arginine vasopressin (AVP) and/or oxytocin (OT) content of individual rat neurohypophysial terminals (NHT) >or=5 microm in diameter, the size used for electrophysiological recordings. We used a commercially available, highly sensitive enzyme-linked immunoassay (ELISA) kit with a sensitivity of 0.25 pg to AVP and of 1.0pg to OT. The NHT content of AVP (2.21+/-0.10 pg) was greater than OT (1.77+/-0.08 pg) and increased with terminal size. AVP-positive terminals (10.2+/-0.21 microm) were larger in diameter than OT-positive terminals (9.1+/-0.24 microm). Immunocytochemical techniques indicated that a higher percentage (58%) of smaller terminals contained OT, and that a higher percentage (42%) of larger NHTs were colabeled. Similar percentages of AVP-positive terminals were obtained between immunocytochemical (73%) and ELISA (72%) methods when NHTs were assayed for AVP alone, but there was a higher percentage of OT terminals when using immunocytochemistry (43%) compared to ELISA (26%). The percent of AVP-positive (60%) and OT-positive (18%) terminals decreased when NHT were assayed for both AVP and OT. Therefore, the best method to reliably identify AVP-positive NHTs is to assay only for AVP, since this allows the conclusion that AVP-negative terminals contain only OT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452053     DOI: 10.1016/j.jneumeth.2007.03.006

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  8 in total

1.  Differential modulation of N-type calcium channels by micro-opioid receptors in oxytocinergic versus vasopressinergic neurohypophysial terminals.

Authors:  Sonia I Ortiz-Miranda; Govindan Dayanithi; Cristina Velázquez-Marrero; Edward E Custer; Steven N Treistman; José R Lemos
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

Review 2.  Purinergic receptor types in the hypothalamic-neurohypophysial system.

Authors:  José R Lemos; Edward E Custer; Sonia Ortiz-Miranda
Journal:  J Neuroendocrinol       Date:  2018-03-07       Impact factor: 3.627

Review 3.  Modulation/physiology of calcium channel sub-types in neurosecretory terminals.

Authors:  José R Lemos; Sonia I Ortiz-Miranda; Adolfo E Cuadra; Cristina Velázquez-Marrero; Edward E Custer; Taimur Dad; Govindan Dayanithi
Journal:  Cell Calcium       Date:  2012-02-17       Impact factor: 6.817

4.  P2X purinergic receptor knockout mice reveal endogenous ATP modulation of both vasopressin and oxytocin release from the intact neurohypophysis.

Authors:  E E Custer; T K Knott; A E Cuadra; S Ortiz-Miranda; J R Lemos
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

Review 5.  Electrophysiological properties of identified oxytocin and vasopressin neurones.

Authors:  William E Armstrong; Robert C Foehring; Matthew K Kirchner; Celia D Sladek
Journal:  J Neuroendocrinol       Date:  2019-02-14       Impact factor: 3.627

6.  Effects of calcium and sodium on ATP-induced vasopressin release from rat isolated neurohypophysial terminals.

Authors:  E E Custer; T K Knott; S Ortiz-Miranda; J R Lemos
Journal:  J Neuroendocrinol       Date:  2018-05-04       Impact factor: 3.627

7.  P2X7 receptors in neurohypophysial terminals: evidence for their role in arginine-vasopressin secretion.

Authors:  Adolfo E Cuadra; Edward E Custer; Elizabeth L Bosworth; José R Lemos
Journal:  J Cell Physiol       Date:  2014-03       Impact factor: 6.384

8.  Functional ryanodine receptors in the membranes of neurohypophysial secretory granules.

Authors:  James M McNally; Edward E Custer; Sonia Ortiz-Miranda; Dixon J Woodbury; Susan D Kraner; Brian M Salzberg; José R Lemos
Journal:  J Gen Physiol       Date:  2014-06       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.